Prior Authorization of Pituitary Suppressive Agents, LHRH - Pharmacy Services
Customize your policy alerts
Sign up for all Pennsylvania Insurance Department policy alerts
Know when Pennsylvania Insurance Department releases new policies or updates existing guidance.
Monitor payer policy activity
Defines prior authorization requirements and medical necessity criteria for pituitary suppressive agents (LHRH) for all licensed pharmacies and prescribers enrolled in Pennsylvania Medical Assistance, including FFS and MA MCOs.
The Department updated medical necessity guidelines to reflect the current title of the World Professional Association for Transgender Health Standards of Care for the Health of Transgender and Gender Diverse People.
Coverage and Medical Necessity Criteria
inv-01: Medical necessity criteria — Covered when ALL of the following are met
Covered when ALL of the following are met
Section B items 1–4
Section B item 5
Section B item 6
Section B item 7
Section B item 8
Section B item 9
Section B item 10
Section B item 11
Section B item 12
There are no additional explicit exclusions beyond standard medication contraindications and adherence to quantity‑limit rules. Determinations for prescriptions that exceed established quantity limits will consider the Quantity Limits Chapter and the accompanying drug list and limits. Standard contraindications to the prescribed medication remain applicable and will be considered during medical necessity review.
If a request does not meet the clinical review guidelines in Section B, it will be referred to a physician reviewer for a medical necessity determination. Such a request may still be approved only when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the beneficiary’s needs; otherwise it may be found not medically necessary.
Coding and Age / Trial Thresholds
Provider Requirements, Authorization, and Denial Risk
Prior authorization required for all LHRH prescriptions
All prescriptions for Pituitary Suppressive Agents, LHRH require prior authorization before dispensing.
Failure/contraindication to preferred agents required for non-preferred
For non-preferred Pituitary Suppressive Agents, LHRH, prior authorization will only be granted when there is a documented history of therapeutic failure of, or a contraindication or intolerance to, preferred Pituitary Suppressive Agents for the beneficiary’s indication (see Preferred Drug List).
- See Preferred Drug List at https://papdl.com/preferred-drug-list for which agents are preferred.
Follow handbook submission procedures and include required clinical documentation
Follow the procedures in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook when submitting prior authorization requests and include the clinical information required by the Section II clinical review guidelines; quantity‑limit exceedances must include documentation per the Quantity Limits Chapter.
- Handbook procedures in SECTION I must be followed per 55 Pa. Code § 1101.67(a).
- If the requested quantity exceeds limits, provide documentation as described in the Quantity Limits Chapter and the online list of quantity‑limited drugs.
Risk of denial when Section B criteria are not met
If the request does not meet the clinical guidelines in Section B, it will be referred to a physician reviewer for a medical necessity determination and may be denied if the physician reviewer does not find the service medically necessary.
- Requests meeting Section B guidelines will be prior authorized by the reviewer; those that do not will be escalated to a physician reviewer.
- A request may still be approved if the physician reviewer determines, in professional judgment, the service is medically necessary.
Initial Therapy Requirements by Indication
inv-12: Initial therapy criteria — Indication-specific initial therapy requirements
Indication-specific initial therapy requirements
Section B item 8
Step Therapy / Preferred Agent Requirements
| Step | Requirement | Notes |
|---|---|---|
| 1 | History of therapeutic failure of, or a contraindication or intolerance to, preferred Pituitary Suppressive Agents (LHRH) | Required before non-preferred Pituitary Suppressive Agents, LHRH are authorized; see Preferred Drug List (https://papdl.com/preferred-drug-list) |
Quantity Limits and Related Constraints
Key Definitions
Background
Pituitary suppressive agents (LHRH agonists and antagonists) are used for multiple clinical indications including central precocious puberty, pubertal suppression for gender dysphoria (adolescents and adults when managed consistent with current WPATH Standards of Care), endometriosis, preservation of ovarian function during gonadotoxic cancer therapy, and management of heavy menstrual bleeding associated with uterine leiomyomas when specific agents are indicated. The policy bulletin updates medical necessity guidance to align transgender care criteria with current WPATH Standards of Care and specifies indication‑specific requirements such as age thresholds, prior therapy trials, and behavioral health assessment for certain agents.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.